SCIENCE · EVIDENCE BASE
Science & Publications
The Genobot platform rests on published research in DNA nanotechnology, most of it carried out at The Ohio State University and continued by the company’s founding scientists. This page lists that work and marks clearly which results carry DNA Nanobots authors, which come from the wider academic field, and which have not been through external peer review.
Peer-reviewed research
Published in journals after external review. The author lists include DNA Nanobots scientists.
Foundational academic work
Published by collaborators and advisors. It establishes the field the platform builds on. It is not Genobot performance data.
Conference material
Posters and abstracts presented at scientific meetings. Useful signal, but not held to the same review standard as a journal article.
TIER ONE
Peer-reviewed research
Four published studies that the platform is built on, listed newest first. Each carries at least two DNA Nanobots scientists as authors.
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Jeremy E, Artiga E, Elgamal S, Cheney C, … Beshay P, Halley PD, Castro CE, Lucas CR, … Byrd JC, Larkin KT.
Blood Advances, 2025;9(1):1–14. PMID 39348689. Open access.
Identifies and characterises a cell-surface target in acute myeloid leukemia and evaluates it as a route for directed delivery. Carolyn Cheney, Patrick Halley, Carlos Castro, Chris Lucas and John Byrd are all among the authors.
DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo
Lucas CR, Halley PD, et al.
Small, 2022;18(26):e2108063. PMID 35633287. Open access.
The platform-safety paper. It examines how DNA origami nanostructures themselves behave across a dose range in vivo, rather than testing any particular payload. Chris Lucas is first author and Patrick Halley second; Larry Beaver is also an author.
Low-cost, simple, and scalable self-assembly of DNA origami nanostructures
Halley PD, Patton RA, Chowdhury A, Byrd JC, Castro CE.
Nano Research, 2019;12(5):1207–1215.
A manufacturing method paper. It addresses the practical obstacle that had kept DNA origami confined to research labs, reporting folding at substantially larger scale and lower cost than prior approaches.
Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model
Halley PD, Lucas CR, McWilliams EM, et al.
Small, 2016;12(3):308–320. PMID 26583570.
The earliest of the four and the origin of the whole approach. Patrick Halley is first author and Chris Lucas second. The payload here was a chemotherapy agent, not a gene. What it established was that a folded DNA structure can carry a payload into cells and change how that payload behaves.
TIER TWO
Foundational academic work
Research from the wider field that establishes what the platform builds on. These are not DNA Nanobots results and nothing here should be read as evidence of Genobot performance.
CRISPR-Cas9-mediated nuclear transport and genomic integration of nanostructured genes in human primary cells
Lin-Shiao E, et al.; Castro CE and Doudna JA among the authors.
Nucleic Acids Research, 2022;50(3):1256–1268. PMID 35104875. Open access.
Directly relevant prior art on moving structured DNA into the nucleus of primary human cells. Enrique Lin-Shiao, who sits on the Scientific Advisory Board, is first author, and Carlos Castro is among the authors. No DNA Nanobots employee is an author on this paper and the company makes no claim to the results reported in it.
TIER THREE
Conference material
Presented at scientific meetings and not through journal peer review. Read these as work in progress rather than as settled results.
Enhanced payload delivery for acute myeloid leukemia treatment through CD37-targeting DNA nanobots
AACR Annual Meeting 2024, Abstract 479.
Cancer Research, 2024;84(6_Supplement):479.
Further posters presented at AACR in 2023 and 2024 are available on request.
Intellectual property
The scientific foundation of the Genobot platform originates in DNA nanotechnology research conducted at The Ohio State University. Patent filings arising from that research are held by Ohio State Innovation Foundation, the university’s technology commercialisation entity, and name company co-founders among the inventors. Specific questions about intellectual property are handled directly rather than published here.
Want the detail behind any of this?
We are happy to walk through the data with scientific and business development teams, including material that is not public.